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(n=332)	 Post-flight	(n=329)	 P	value	 Normal	Reference	
Values*	Total	Volume	(L/d)	 2.1	±	0.06	 2.0	±	0.06	 NS	 2-2.5	<1	L/d		 13.0%	 13.1%	 	 -	<1-2	L/d		 38.9%	 46.2%	 	 -	>2	L	d																														 48.2%	 40.7%	 	 -	Oxalate	(mg/d)	 38	±	0.9														 37	±	0.9	 NS	 0-45		Calcium	(mg/d)	 183	±	5.3		 	234	±	6																	 <0.05	 <300	M	<250	F	pH	 6.05	±	0.02										 5.79	±	0.03												 <0.05	 4.5-8.0	Citrate	(mg/d)																		714	±	16														 629	±	18																 <0.05	 >	320	Magnesium	(mg/d)	 116.0	±	2.5	 99.0	±	2.2															 NS	 75-120	Values	are	Mean	±	SEM;	L/d	–	liters	per	day.		Pre-flight	urines	collected	10	days	before	launch	and	post-flight	urines	collected	on	landing	following	missions	of	<16	days.		*Johnson	Space	Center	Clinical	Laboratory	and	Johnson	Space	Center	Cellular	and	Biomedical	Laboratory.		
Table	2.		Mean	Values	for	Relative	Saturation	of	Stone-Forming	Salts	in	Urine	from	Crewmembers	during	Short-Duration	Spaceflight				 														
Parameter			 Pre-flight	n=332	 	 Post-flight																n=329	 P	value		 Normal		Reference		
Value	Calcium	Oxalate	 1.53	±	0.06	 2.26	±	0.07	 	<0.05	 <	2.0	Brushite	 1.25	±	0.06									 1.00	±	0.06	 	<0.05	 <	2.0	Sodium	urate																			 	2.41	±	0.11									 1.42	±	0.07	 <0.05	 <	2.0	Struvite	 3.05	±	0.83									 3.69	±	2.21													 NS	 <	75.0	uric	H+																														 1.69	±	0.08										 2.27	±	0.09										 <0.05	 <	2.0	





Abnormality	 Pre-flight	 Post-flight		Hypercalciuria	(>250	mg/d)	 20.8%																			38.9%	Hypocitraturia	(<320	mg/d)							 6.9%	 14.6%	Hypomagnesuria	(<60	mg/d)				 6.0%																		15.8%	Urinary	supersaturation	(>2.0)	 	 	Calcium	oxalate	 25.6	%	 46.2	%	Uric	Acid	 32.8	%	 48.6	%	Brushite	 19.3	%	 13.1	%	Sodium	urate	 44.9	%	 25.8	%		
Table	4.		Urinary	Tract	Stone	Events	in	the	Astronaut	Corps	(as	of	mid-2016)	Time	 #	of	Events	 Comments	Prefight	 5	 Before	flight,	no	previous	flight	experience	R+0	to	90	days	 1	 	R+90	to	180	days*	 3	 	R+180	to	270	days*	 1	 	R+270	to	360	days	*	 2	 	Inter-flight	 4	 Greater	than	360	days	post-flight,	but	flew	again	R	>	360	days	(Active)	 2	 Greater	than	360	days	and	never	flew	again	Post	NASA	Career	 19	 	Total		 37	 	All	U.S.	Astronauts	(n=357).	Total	number	of	crewmembers	reporting	events	=	37.	*No	cases	in	this	interval	reported	pre-flight	events.	R+:	number	of	days	post-flight.	Post	NASA	Career	=	event	occurred	following	retirement	from	active	astronaut	duty.		In	a	series	of	investigations	led	by	Peggy	Whitson,	Ph.D,	environmental	and	biochemical	risk	factors	for	renal	stone	formation	were	extensively	characterized	for	both	short-	and	longer-duration	missions.	It	was	first	reported	that	an	increased	risk	of	calcium	oxalate	and	uric	acid	stone	formation	was	evident	immediately	after	spaceflight,	concurrent	with	the	hypercalciuria	and	hypocitraturia	quantified	after	return	(Whitson	et	al.	1993).	Further	investigation,	which	included	analysis	of	urine	collected	during	flight,	revealed	that	many	of	the	contributing	factors	to	renal	stone	formation	associated	with	spaceflight	were	related	to	nutrition,	urinary	pH,	and	volume	output	(Whitson	et	al.	1997).	In	addition,	biochemical	analysis	of	urine	specimens	obtained	during	longer	Space	Shuttle	missions	provided	a	temporal	reflection	of	the	risk,	indicating	that	the	increased	risk	for	renal	stone	formation	occurs	rapidly	during	spaceflight,	continues	throughout	the	mission,	and	persists	following	landing	(Whitson	et	al.	1999).	In-flight	evidence	from	Space	Shuttle	missions	associated	urinary	supersaturation	and	decreased	urine	excretion	with	reduced	fluid	intake;	further,	increasing	the	volume	of	urine	output	effectively	reduced	the	urine	









































To	Earth	(days)	Short	 Moon	 3	 8	 3	Long	 Moon	 5	 170	 5	Short	 Mars	 162	 40	 162	Long	 Mars	 189	 540	 189		
Probability	Estimation	for	Renal	Stone	Event	In	the	absence	of	space	flight	incidence	of	renal	stones	in	the	U.S.	astronaut	population,	the	IMM	database	and	modeling	tool	has	been	used	to	project	an	estimation	of	the	likelihood	of	stone	occurrence	as	well	as	the	outcome	of	various	treatment	strategies.	Estimate	incidence	rates	were	generated	by	Bayesian	methods,	using	data	from	NASA’s	Lifetime	Surveillance	of	Astronaut	Health	(LSAH)	and	population	data	from	the	Centers	for	Disease	Control	(CDC)	(Litwin	and	Saigal	2012).	Due	to	this	low	occurrence,	Bayesian	methods	were	deemed	necessary	in	order	to	better	predict	probability	estimates	for	incidence	rates	of	this	medical	event.	The	Bayesian	process	allows	researchers	to	make	inferences	to	determine	the	probability	that	a	hypothesis	is	true,	conditional	on	all	available	evidence.	Information	from	these	sources	was	combined	using	a	Bayesian	update	approach	to	estimate	the	average	rate	of	stone	formation.	By	making	an	average	rate	assumption,	a	Poisson	probability	distribution	was	assumed	to	govern	the	probability	of	stone	formation.	This	model	used	only	data	pertaining	to	stone	occurrence,	not	data	related	to	blood	or	urine	chemistry.		From	the	CDC,	as	of	2004,	the	incidence	of	renal	stones	in	males	was	1-3	events	per	1000	persons	per	year	and	0.6-1	events	per	1000	persons	per	year	in	females.	For	this	spaceflight	analysis,	gender	differences	were	not	considered	since	the	vast	majority	of	astronauts	were	male;	the	resultant	average	incidence	rate	of	renal	stones	was	0.0018	per	year.	Along	with	tracking	current	and	former	astronauts,	the	LSAH	maintains	an	astronaut	control	population	database	primarily	made	up	of	NASA	Johnson	Space	Center	




Table	5.		Probability	of	a	renal	stone	event	during	spaceflight	missions.	Mission	 Probability	per	person	year	of	one	or	more	in	one	crewmember	Any	Event	 Best	Case	 Worst	Case	Lunar	Sortie	(21	day)	 0.0002	(0.02%)	 0.0001	(0.01%)	 0.0001	(0.01%)	ISS	(6	month)	 0.0018	(0.18%)	 0.0011	(0.11%)	 0.0007	(0.07%)	Mars	(3	years)	 0.019	(1.90%)	 0.0066	(0.66%)	 0.0043	(0.43%)	Best	Case	Scenario	–	a	renal	stone	that	responds	to	conservative	treatment	(analgesics,	hydration)	Worst	Case	Scenario	–	a	renal	stone	that	requires	advanced	medical	intervention		These	risk	predictions	should	be	considered	very	limited	in	that	they	assume	an	average	occurrence	rate	of	renal	stones,	irrespective	of	the	stone	type	or	environmental	conditions.		Additionally,	the	inclusion	of	repeated	occurrences	could	influence	the	predicted	rate	of	incidences,	as	it	is	known	that	the	occurrence	of	one	stone	increases	the	likelihood	of	subsequent	stones.	However,	it	is	likely	a	reasonable	representation	of	the	rate	of	stone	formation	given	the	occurrence	data	available	and	given	the	assumptions	made	during	construction	of	the	estimate.	Future	models	will	include	these	data	to	improve	the	estimate	of	the	rate	of	occurrence	in	the	astronaut	corps.	More	accurate	estimates	can	be	made	with	further	analysis	of	the	periods	of	renal	stone	occurrence	in	post-flight	nephrolithiasis	cases	
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